PavelKleinMD

Epilepsy, Neurophysiology

Neurologist in Bethesda, Maryland and is affiliated with multiple hospitals in the area, including Adventist Healthcare Shady Grove Medical Center and Holy Cross Hospital

Join to view full profile

Dr. Klein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Klein's full profile

Already have an account?

Office
6410 Rockledge Dr
610
Bethesda, MD 20817
Phone+1 301-530-9744

Fax+1 301-530-0046
Is this information wrong?

Education & Training

Beth Israel Deaconess Medical Center/Children's Hospital/Harvard Medical SchoolFellowship, Clinical Neurophysiology, 1998
University of Cambridge School of MedicineClass of 1980

Certifications & Licensure

NJ State Medical License 2022 - 2025
MD State Medical License 1998 - 2024
VA State Medical License 1989 - 2024
DC State Medical License 1999 - 2013
MA State Medical License 1994 - 2000
GA State Medical License 1990 - 1997
TN State Medical License 1990 - 1996
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Epilepsy

Awards, Honors, & Recognition

Top Doctors:Washington DC Area Castle Connolly, 2012
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013
Join now to see all

Clinical Trials

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy Start of enrollment: 2010 Jun 01
Completed
Phase 3
Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study Start of enrollment: 2013 Jan 01
Completed
Phase 1
Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy Start of enrollment: 2013 Jan 01
Unknown status
Phase 2
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension Start of enrollment: 2013 Oct 01
Completed
Phase 3
Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea Start of enrollment: 2014 Jan 01
Unknown status
Phase 2
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures Start of enrollment: 2016 Aug 03
Completed
Phase 3
Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study. Start of enrollment: 2015 Nov 01
Terminated
Phase 4
Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures Start of enrollment: 2017 Aug 23
Completed
Phase 4
Treatment of Type 2 Diabetes With Ketogenic Diet Start of enrollment: 2017 Nov 01
Unknown status
Not Applicable
Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy Start of enrollment: 2020 Jun 25
Recruiting
A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome Start of enrollment: 2022 Mar 04
Recruiting
Phase 3
Roles: Principal Investigator
Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Start of enrollment: 2015 Feb 01
Unknown status
Phase 4
Roles: Principal Investigator, Contact, Sponsor-Investigator
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome Start of enrollment: 2021 Nov 08
Completed
Phase 3
Roles: Principal Investigator
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures Start of enrollment: 2020 Jan 27
Recruiting
Phase 2
Roles: Contact
Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy Start of enrollment: 2021 Aug 31
Active, not recruiting
Phase 2
Roles: Contact
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH Start of enrollment: 2022 Dec 28
Active, not recruiting
Phase 2
Roles: Contact
Cortical Excitability in Post-traumatic Epilepsy Start of enrollment: 2022 Aug 01
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the in...
Szaflarski, J., Besson, H., D'Souza, W., Faught, E., Klein, P., Reuber, M., Rosenow, F., Salas-Puig, J., Soto Insuga, V., Steinhoff, B., Strzelczyk, A., Bourikas, D., ...> ;Journal of Neurology. 2024 Mar 4
1 citations
Prevention of epileptogenesis - are we there yet?
Koepp, M., Trinka, E., Löscher, W., Klein, P.> ;Current Opinion in Neurology. 2024 Feb 13
3 citations
Preclinical pharmacokinetics and tolerability of a novel meglumine-based parenteral solution of topiramate and topiramate combinations for treatment of status epilepti...
Chris Rundfeldt, Pavel Klein, Detlev Boison, Alexander Rotenberg, Raimondo D'Ambrosio, Cliff Eastman, Benton Purnell, Madhuvika Murugan, Howard P Goodkin, Wolfgang Lös...> ;Epilepsia. 2023 Apr 1
5 citations
Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc ana...
Christian Brandt, Svetlana Dimova, Sami Elmoufti, Cédric Laloyaux, Xavier Nondonfaz, Pavel Klein> ;Epilepsy & Behavior. 2023 Jan 1
3 citations
EEG parameters as endpoints in epilepsy clinical trials - An expert panel opinion paper.
Jeffrey Buchhalter, Caroline Neuray, Jocelyn Y Cheng, O'Neill D'Cruz, Alexandre N Datta, Dennis Dlugos, Jacqueline French, Dietrich Haubenberger, Joseph Hulihan, Pavel...> ;Epilepsy Research. 2022 Nov 1
19 citations
Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations.
Michael C Smith, Pavel Klein, Gregory L Krauss, Samiya Rashid, Lawrence G Seiden, John M Stern, William E Rosenfeld> ;Neurology and Therapy. 2022 Dec 1
22 citations
Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures.
Pavel Klein, Sami Aboumatar, Christian Brandt, Fang Dong, Gregory L Krauss, Sarah Mizne, Bernhard J Steinhoff, Vicente Villanueva, Sánchez-Álvarez, J.> ;Neurology. 2022 Sep 5
7 citations
Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study.
Bassel Abou-Khalil, Sami Aboumatar, Pavel Klein, Gregory L Krauss, Michael R Sperling, William E Rosenfeld> ;Epilepsy Research. 2022 Aug 1
3 citations
Intravenous Brivaracetam in the Management of Acute Seizures in the Hospital Setting: A Scoping Review.
Kiwon Lee, Pavel Klein, Prashant Dongre, Eun Jung Choi, Denise H Rhoney> ;Journal of Intensive Care Medicine. 2022 Sep 1
Comments on the Evaluation of Suicidality Risk of Newer Antiseizure Medications-Reply.
Pavel Klein, Robert McCarter, Michael R Sperling> ;JAMA Neurology. 2022 Mar 1
11 citations
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials.
Amanda W Pong, Jonathan Ross, Ivana Tyrlikova, Alexander J Giermek, Maya P Kohli, Yousef A Khan, Roger D Salgado, Pavel Klein> ;Expert Opinion on Emerging Drugs. 2022 Mar 1
23 citations
Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant an...
William E. Rosenfeld, Bassel Abou-Khalil, Sami Aboumatar, Perminder Bhatia, Victor Biton, Gregory L. Krauss, Michael R. Sperling, David G. Vossler, Pavel Klein, Robert...> ;Epilepsia. 2021 Oct 11
22 citations
Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.
Michael R. Sperling, Bassel Abou-Khalil, Sami Aboumatar, Perminder Bhatia, Victor Biton, Pavel Klein, Gregory L. Krauss, David G. Vossler, Robert T. Wechsler, Louis Fe...> ;Epilepsia. 2021 Oct 11
9 citations
Therapeutic Effects of Time-limited Treatment with Brivaracetam on Posttraumatic Epilepsy after Fluid Percussion Injury in the Rat
Clifford L. Eastman, Jason S. Fender, Pavel Klein, Raimondo D'Ambrosio> ;The Journal of Pharmacology and Experimental Therapeutics. 2021 Sep 30
6 citations
Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy-expert opinion.
Bernhard J. Steinhoff, William E. Rosenfeld, José M. Serratosa, Christian Brandt, Pavel Klein, Manuel Toledo, Gregory L. Krauss> ;Epilepsy & Behavior. 2021 Sep 8
26 citations
Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis.
Pavel Klein, Orrin Devinsky, Jacqueline A. French, Cynthia L. Harden, Gregory L. Krauss, Robert McCarter, Michael R. Sperling> ;JAMA Neurology. 2021 Sep 1
13 citations
Antiepileptogenesis and disease modification: Clinical and regulatory issues
Jacqueline A. French, Martina Bebin, Marc A. Dichter, Jerome Engel, Adam L. Hartman, Sergiusz Jóźwiak, Pavel Klein, James O. McNamara, Twyman Roy E, Paul M. Vespa> ;Epilepsia Open. 2021 Sep 1
Correction to: The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.
Wolfgang Löscher, Pavel Klein> ;CNS Drugs. 2021 Aug 17
19 citations
New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?
Wolfgang Löscher, Pavel Klein> ;Pharmacology & Therapeutics. 2021 Jun 30
85 citations
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
Wolfgang Löscher, Pavel Klein> ;CNS Drugs. 2021 Jun 18
38 citations
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Bernhard J. Steinhoff, Pavel Klein, Henrik Klitgaard, Cédric Laloyaux, Brian D. Moseley, Kristen Ricchetti-Masterson, Felix Rosenow, Joseph I Sirven, Brien J. Smith, J...> ;Epilepsy & Behavior. 2021 Apr 8
10 citations
Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial.
Manuel Toledo, Christian Brandt, Pier Paolo Quarato, Anne-Liv Schulz, Jody M. Cleveland, Gilbert Wagener, Pavel Klein> ;Epilepsy & Behavior. 2021 May 1
8 citations
Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepilep...
Lisa Welzel, David H. Bergin, Alina Schidlitzki, Friederike Twele, Marie Johne, Pavel Klein, Wolfgang Löscher> ;Neurobiology of Disease. 2021 Feb 1
20 citations
Treatment of glioblastoma multiforme with “classic” 4:1 ketogenic diet total meal replacement
Pavel Klein, Ivana Tyrlíková, Giulio Zuccoli, Adam Tyrlik, Joseph C. Maroon> ;Cancer & Metabolism. 2020 Nov 9
24 citations
Seizure clusters, rescue treatments, seizure action plans: Unmet needs and emerging formulations.
Barry E. Gidal, Pavel Klein, Lawrence J. Hirsch> ;Epilepsy & Behavior. 2020 Sep 6
Join now to see all

Press Mentions

Expert Consensus Opinions Published in Neurology and Therapy Discuss Adjustment of Anti-Seizure Medication Dosing for Optimal CareSeptember 12th, 2022
'No Evidence' Newer Antiseizure Medications Increase Risk for SuicidalityAugust 9th, 2021
Novela Neurotech Joins the 2021 UCSF Rosenman InnovatorsJune 17th, 2021
Join now to see all